Janus Henderson Global Life Sciences Fund Class A (JFNAX)

Fund Assets	5.25B
Expense Ratio	0.98%
Min. Investment	$2,500
Turnover	34.00%
Dividend (ttm)	3.80
Dividend Yield	5.38%
Dividend Growth	32.57%
Payout Frequency	Annual
Ex-Dividend Date	Dec 6, 2024

Previous Close	66.22
YTD Return	-1.93%
1-Year Return	n/a
5-Year Return	38.54%
52-Week Low	66.22
52-Week High	80.59
Beta (5Y)	0.70
Holdings	109
Inception Date	Jul 6, 2009

About JFNAX

The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

• Fund Family: Janus Henderson
• Category: Health
• Performance Rating: Above Average
• Risk Rating: Average
• Stock Exchange: NASDAQ
• Ticker Symbol: JFNAX
• Index: MSCI World/Health Care NR

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
JFNNX	Class N	0.67%
JFNIX	Class I	0.77%
JNGLX	Class D	0.80%
JAGLX	Class T	0.92%

Top 10 Holdings

41.29% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	8.67%
UnitedHealth Group Incorporated	UNH	6.82%
Novo Nordisk A/S	NOVO.B	4.48%
AbbVie Inc.	ABBV	3.82%
AstraZeneca PLC	AZN	3.54%
Amgen Inc.	AMGN	3.42%
Johnson & Johnson	JNJ	2.81%
Sanofi	SAN	2.67%
Boston Scientific Corporation	BSX	2.59%
Vertex Pharmaceuticals Incorporated	VRTX	2.47%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 6, 2024	$3.8026	Dec 6, 2024
Dec 7, 2023	$2.86828	Dec 7, 2023
Dec 20, 2022	$0.04945	Dec 20, 2022
Dec 20, 2021	$6.7078	Dec 20, 2021
Dec 17, 2020	$5.47231	Dec 17, 2020
Dec 17, 2019	$3.72423	Dec 17, 2019